Influencing factors of clinical efficacy of roxadustat among hemodialysis patients

References

• Wingard RL, Chan KE, Lazarus JM, et al. The "right" of passage: surviving the first year of dialysis. Clin J Am Soc Nephrol. 2009;4(Suppl. 1):1–7. doi: 10.2215/CJN.04360709.
   Google Scholar
• Liu J, Yang F, Waheed Y, et al. The role of roxadustat in chronic kidney disease patients complicated with anemia. Korean J Intern Med. 2023;38(2):147–156. doi: 10.3904/kjim.2022.318.
   PubMedGoogle Scholar
• Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007;12(4):321–330. doi: 10.1111/j.1440-1797.2007.00810.x.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, White C, Anker SD, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380(5):447–458. doi: 10.1056/NEJMoa1810742.
   PubMed Web of Science ®Google Scholar
• Sakaguchi Y, Hamano T, Wada A, et al. Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis. J Am Soc Nephrol. 2019;30(6):1037–1048. doi: 10.1681/ASN.2018101007.
   PubMed Web of Science ®Google Scholar
• Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017;18(1):345. doi: 10.1186/s12882-017-0688-1.
   PubMed Web of Science ®Google Scholar
• Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394–410. doi: 10.1038/nrneph.2015.82.
   PubMed Web of Science ®Google Scholar
• Bae MN, Kim SH, Kim YO, et al. Association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients. PLOS One. 2015;10(11):e0143348. doi: 10.1371/journal.pone.0143348.
   PubMed Web of Science ®Google Scholar
• Cizman B, Smith HT, Camejo RR, et al. Clinical and economic outcomes of erythropoiesis-stimulating agent hyporesponsiveness in the post-bundling era. Kidney Med. 2020;2(5):589–599.e1. doi: 10.1016/j.xkme.2020.06.008.
   PubMedGoogle Scholar
• Dhillon S. Roxadustat: first global approval. Drugs. 2019;79(5):563–572. doi: 10.1007/s40265-019-01077-1.
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu B-C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019;381(11):1011–1022. doi: 10.1056/NEJMoa1901713.
   PubMed Web of Science ®Google Scholar
• Shutov E, Sułowicz W, Esposito C, et al. Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant. 2021;36(9):1629–1639. doi: 10.1093/ndt/gfab057.
   PubMed Web of Science ®Google Scholar
• Coyne DW, Roger SD, Shin SK, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep. 2021;6(3):624–635. doi: 10.1016/j.ekir.2020.11.034.
   PubMed Web of Science ®Google Scholar
• Charytan C, Manllo-Karim R, Martin ER, et al. A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep. 2021;6(7):1829–1839. doi: 10.1016/j.ekir.2021.04.007.
   PubMed Web of Science ®Google Scholar
• Czock D, Keller F. Clinical pharmacokinetics and pharmacodynamics of roxadustat. Clin Pharmacokinet. 2022;61(3):347–362. doi: 10.1007/s40262-021-01095-x.
   PubMed Web of Science ®Google Scholar
• Hu N, Wu WH, Jiang ZW. Determination of roxadustat in the plasma of hemodialysis patients by LC–MS/MS. Chin J Clin Pharmacol. 2023;39(2):281–285. doi: 10.13699/j.cnki.1001-6821.2023.02.027.
   Google Scholar
• Becker K, Saad M. A new approach to the management of anemia in CKD patients: a review on roxadustat. Adv Ther. 2017;34(4):848–853. doi: 10.1007/s12325-017-0508-9.
   PubMed Web of Science ®Google Scholar
• Abdelazeem B, Shehata J, Abbas KS, et al. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: an updated systematic review and meta-analysis of randomized clinical trials. PLOS One. 2022;17(4):e0266243. doi: 10.1371/journal.pone.0266243.
   PubMed Web of Science ®Google Scholar
• Zheng Q, Yang H, Fu X, et al. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2021;36(9):1603–1615. doi: 10.1093/ndt/gfaa110.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jing Y, Zhou C. Correlation between blood concentration of roxadustat and clinical efficacy in patients with anemia of chronic kidney disease. Medicine. 2023;102(15):e33564. doi: 10.1097/MD.0000000000033564.
   PubMed Web of Science ®Google Scholar
• Chen K, Ma S, Zhang L, et al. Influence of gene polymorphism on efficacy of roxadustat in patients with chronic kidney disease. J Nephrol Dial Transplant. 2022;31(02):133–138. doi:10.3969/j.issn.1006-298X.2022.02.006.
   Google Scholar
• Takada A, Shibata T, Shiga T, et al. Population pharmacokinetics of roxadustat in japanese dialysis-dependent chronic kidney disease patients with anaemia. Brit J Clinical Pharma. 2022;88(2):787–797. doi:10.1111/bcp.15023.
   PubMed Web of Science ®Google Scholar
• Haldar M, Kohyama M, So AY-L, et al. Heme-mediated SPI-C induction promotes monocyte differentiation into iron-recycling macrophages. Cell. 2014;156(6):1223–1234. doi: 10.1016/j.cell.2014.01.069.
   PubMed Web of Science ®Google Scholar
• Ganz T. Erythropoietic regulators of iron metabolism. Free Radic Biol Med. 2019;133:69–74. doi: 10.1016/j.freeradbiomed.2018.07.003.
   PubMed Web of Science ®Google Scholar
• Ogawa C, Tsuchiya K, Maeda K. Hypoxia-inducible factor prolyl hydroxylase inhibitors and iron metabolism. Int J Mol Sci. 2023;24(3):3037. doi: 10.3390/ijms24033037.
   PubMed Web of Science ®Google Scholar
• Bradbury BD, Critchlow CW, Weir MR, et al. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in ­hemodialysis patients. Nephrol Dial Transplant. 2009;24(3):919–925. doi: 10.1093/ndt/gfn543.
   PubMed Web of Science ®Google Scholar
• Kanbay M, Perazella MA, Kasapoglu B, et al. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif. 2010;29(1):1–12. doi: 10.1159/000245041.
   PubMed Web of Science ®Google Scholar
• de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus. 2009;2(Suppl. 1):i18–i26. doi: 10.1093/ndtplus/sfn176.
   PubMedGoogle Scholar
• Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628–1639. doi: 10.1681/ASN.2019060623.
   PubMed Web of Science ®Google Scholar
• Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823(9):1434–1443. doi: 10.1016/j.bbamcr.2012.01.014.
   PubMed Web of Science ®Google Scholar
• Knutson MD, Oukka M, Koss LM, et al. Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin. Proc Natl Acad Sci U S A. 2005;102(5):1324–1328. doi: 10.1073/pnas.0409409102.
   PubMed Web of Science ®Google Scholar
• Portolés J, Martín L, Broseta JJ, et al. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med. 2021;8:642296. doi: 10.3389/fmed.2021.642296.
   PubMedGoogle Scholar